PSMA PET Scan Era: A Changing Paradigm PSMA PET and Lymph Node Dissection for Prostate Cancer Management

被引:1
|
作者
Haxhimolla, Julia [1 ]
Kua, Boon [2 ]
Gilbourd, Daniel [3 ]
Haxhimolla, Hodo [3 ]
机构
[1] Univ Canberra, Canberra, ACT, Australia
[2] Wesley Hosp Brisbane, Auchenflower, Qld, Australia
[3] ANU Canberra, ACT Hlth, Canberra, ACT, Australia
关键词
Prostate cancer; PSMA PET scan; Pelvic lymph node dissection; Radical prostatectomy; MEMBRANE ANTIGEN-EXPRESSION; RADICAL PROSTATECTOMY; PELVIC LYMPHADENECTOMY; GA-68-PSMA PET/CT; LOCAL TREATMENT; EAU GUIDELINES; DIAGNOSIS; EXTENT;
D O I
10.1016/j.soncn.2020.151044
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Staging of extra-prostatic prostate cancer has traditionally been assessed by computerised tomography (CT), bone scan, and where indicated, pelvic lymph node dissection at the time of surgery. The advent of the prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scan shows promise in improving the accuracy of preoperative staging of this cancer. The role of pelvic lymph node dissection and its associated morbidity will be examined. This article will review current literature assessing the current role of PSMA PET and lymph node dissection in the staging and treatment of prostate cancer. Data sources: Peer-reviewed literature and databases, including Medline and PubMed. Conclusions: PSMA PET/CT appears to be a promising and superior staging investigation that may replace bone scan and CT scan in guiding treatment decision-making. It has high specificity and positive predictive value, thus in patients with low-risk prostate cancer, unnecessary extended pelvic lymph node dissection (ePLND) may be avoided. It would also help detect lymph nodes in patients with intermediateor high-risk prostate cancer where ePLND may be required. ePLND remains the gold standard in staging high-risk patients because the PSMA PET/CT scan may under-stage the cancer. Implication for Nursing Practice: Given the increased utilisation of PSMA PET/CT scan as a primary staging investigation in clinical practice for prostate cancer and as an alternative to bone scan and CT scan, it is timely for prostate cancer specialist nurses to understand and recognise the specificity and sensitivity of PSMA PET/CT scans in prostate cancer staging. Because ePLND is the gold standard for staging high-risk disease, prostate cancer specialist nurses should be aware of the complications associated with pelvic lymph node dissection to optimise supportive care for men affected by complications from ePLND. Crown Copyright (C) 2020 Published by Elsevier Inc. All rights reserved.
引用
收藏
页数:4
相关论文
共 50 条
  • [1] Impact of PSMA PET scan on prostate cancer management
    Baxi, Hemang
    Mayank, Manas
    Kallur, Kumar
    BJU INTERNATIONAL, 2015, 116 : 19 - 19
  • [2] Is extended pelvic lymph node dissection REALLY required for staging of prostate cancer in the PSMA-PET era?
    Roberts, Matthew J.
    Yaxley, John W.
    Stranne, Johan
    van Oort, Inge M.
    Tilki, Derya
    PROSTATE CANCER AND PROSTATIC DISEASES, 2024,
  • [3] The role of salvage lymph node dissection and PSMA-PET in recurrent prostate cancer Comment
    Kalampokis, Nikolaos
    Grivas, Nikolaos
    GLAND SURGERY, 2020, 9 (04) : 1080 - 1081
  • [4] Are PSMA PET/CT scans changing the management of prostate cancer?
    Merrett, C.
    Silagy, B.
    Namdar, K.
    Shum, P. L.
    Vu, J.
    Manohar, P.
    BJU INTERNATIONAL, 2020, 125 : 106 - 106
  • [5] Can pelvic lymph node dissection be skipped in prostate cancer patient based on PSMA-PET?
    Chan, M. W. L.
    Chan, V.
    Wong, C. H. M.
    Wong, F. C. H.
    Chan, S. Y. S.
    Li, J. K. M.
    Chan, W. H. C.
    Ng, A. C. F.
    BJU INTERNATIONAL, 2023, 131 : 10 - 10
  • [6] Impact of PSMA PET on Prostate Cancer Management
    Adam B. Weiner
    Raag Agrawal
    Luca F. Valle
    Ida Sonni
    Amar U. Kishan
    Matthew B. Rettig
    Steven S. Raman
    Jeremie Calais
    Paul C. Boutros
    Robert E. Reiter
    Current Treatment Options in Oncology, 2024, 25 : 191 - 205
  • [7] Impact of PSMA PET on Prostate Cancer Management
    Weiner, Adam B.
    Agrawal, Raag
    Valle, Luca F.
    Sonni, Ida
    Kishan, Amar U.
    Rettig, Matthew B.
    Raman, Steven S.
    Calais, Jeremie
    Boutros, Paul C.
    Reiter, Robert E.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, 25 (02) : 191 - 205
  • [8] PSMA PET in Prostate Cancer
    Jadvar, Hossein
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (08) : 1131 - 1132
  • [9] PSMA PET/CT and Sentinel Node Biopsy for Primary Lymph Node Staging in Prostate Cancer
    Hinsenveld, F.
    Wit, E. M. K.
    Van Leeuwen, P. J.
    Brouwer, O. R.
    Donswijk, M. L.
    Tillier, C. N.
    Vegt, E.
    Van Muilekom, H. A. M.
    Van Oosterom, M.
    Van Leeuwen, F. W. B.
    Van der Poel, H. G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S278 - S278
  • [10] Stereotactic Body Radiation Therapy Salvage for Lymph Node Recurrent Prostate Cancer in the Era of PSMA PET Imaging
    Omar E. Hayek
    Soroush Rais-Bahrami
    Andrew McDonald
    Samuel J. Galgano
    Current Urology Reports, 2023, 24 : 471 - 476